
Canaccord lowered the firm’s price target on First Tracks Biotherapeutics (TRAX) to $57 from $60 and keeps a Buy rating on the shares. The firm said they reported operating expenses
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| TRAX | First Tracks Biotherapeutics Inc | 41.64 | 23.85 | 134.00% |
| Name | Price | % Change | |
|---|---|---|---|
| $41.64 | +134.00% |

Canaccord lowered the firm’s price target on First Tracks Biotherapeutics (TRAX) to $57 from $60 and keeps a Buy rating on the shares. The firm said they reported operating expenses

Guggenheim raised the firm’s price target on First Tracks Biotherapeutics (TRAX) to $110 from $100 and keeps a Buy rating on the shares. Published first on TheFly – the ultimate

“ANB033, a subcutaneously administered CD122 antagonist designed to inhibit signaling of both IL-15 and IL-2 on immune cells, demonstrated statistically significant protection against gluten-induced intestinal damage and symptoms and was

This filing relates to the offer and sale from time to time by the selling stockholders of up to 6.1M shares of common stock. The company is not selling any

First Tracks Biotherapeutics (TRAX) announced that it has entered into a securities purchase agreement to sell 6,106,870 shares of its common stock to a limited group of institutional investors in

J.P. Morgan analyst Anupam Rama has maintained their bullish stance on TRAX stock, giving a Buy rating today. Anupam Rama has given his Buy rating due to a combination of

Evercore ISI raised the firm’s price target on First Tracks Biotherapeutics (TRAX) to $70 from $65 and keeps an Outperform rating on the shares. Published first on TheFly – the

Canaccord Genuity analyst Edward Nash has reiterated their bullish stance on TRAX stock, giving a Buy rating today. Edward Nash has given his Buy rating due to a combination of

Canaccord raised the firm’s price target on First Tracks Biotherapeutics (TRAX) to $60 from $50 and keeps a Buy rating on the shares. The firm updated ts model after the

Wells Fargo analyst Derek Archila raised the firm’s price target on First Tracks Biotherapeutics (TRAX) to $70 from $62 and keeps an Overweight rating on the shares. The firm believes
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| buy | Reiterated | Nov 12, 2026 | ||||
| buy | Reiterated | Nov 5, 2026 | ||||
| buy | Reiterated | Nov 5, 2026 | ||||
| buy | Assigned | Nov 4, 2026 | ||||
| buy | Reiterated | Nov 4, 2026 | ||||
| buy | Reiterated | Nov 4, 2026 | ||||
| buy | Reiterated | Nov 4, 2026 | ||||
| buy | Reiterated | Nov 3, 2026 | ||||
| buy | Reiterated | Oct 13, 2026 | ||||
| buy | Reiterated | Sep 3, 2026 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.